Saturday 17 October 2026 Export HELP’s income statement to Excel — free account

Cybin Inc.

In the quarter to June 2026, EPS grew 17.3% and free cash flow fell 25.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

10.55 0.50 −4.52%

Follow HELP

Alert me

Market cap: $807.3M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: n/a
Altman Z: 12.98
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 8.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	7	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.39%

Capital & Financial Ratios $m

Market Cap 807.31

Revenue —

Net Income (171.20)

Free Cash Flow (142.25)

Net Debt (166.36)

Current Ratio 10.97

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.55)

P/S ratio 0.00

P/B ratio 2.28

Past 5Y EPS Growth —

This Y EPS Growth 34.66%

Next Y EPS Growth 19.26%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 26.54%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 54.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	155	94	157	166
Receivables	3	4	5	5
Inventory	—	—	—	—
Other	2	2	—	—
	162	115	185	193

	2024	2025	2026	Q'26
Payables	7	15	19	18
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	15	19	18

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	28.85%	85.20%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(37)	—	—	—	—
’26	(30)	(34)	(32)	(37)	(133)
’25	(20)	(19)	(19)	(15)	(72)
’24	(8)	(9)	(19)	(16)	(51)
’23	(9)	(11)	(7)	(9)	(36)
’22	(7)	(11)	(10)	(8)	(36)
’21	—	—	(10)	(5)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(37)	—	—	—	—
’26	(30)	(35)	(32)	(38)	(135)
’25	(20)	(19)	(19)	(15)	(74)
’24	(8)	(9)	(19)	(16)	(52)
’23	(9)	(13)	(7)	(9)	(38)
’22	(7)	(11)	(10)	(8)	(36)
’21	—	—	(10)	(5)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.91)	—	—	—	—
’26	(1.10)	(1.39)	(1.00)	(0.76)	(4.25)
’25	(0.54)	(2.10)	(0.38)	(1.02)	(4.02)
’24	(1.90)	(1.52)	(2.66)	(1.52)	(7.22)
’23	(2.28)	(1.90)	(1.52)	(1.90)	(7.22)
’22	(2.66)	(3.42)	(3.04)	(3.04)	(12.17)
’21	—	—	(2.66)	(0.07)	(9.51)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	49.99	2.96	36.10	10.07	7.98	6.50	4.81	3.76	Analyst estimates 2027–2029 Powerpack
	High	—	—	49.99	74.63	128.44	46.36	28.04	19.84	10.73	15.15
People
People	Employees	—	—	—	—	38	38	50	50	50	100
	Revenue/emp, $m	—	—	—	—	0.02	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	1	—	—	—	—	—
	Gross margin, %	—	—	—	—	23.15	0.00	0.00	—	—	—
	EBT	0	0	0	—	(24)	(54)	(36)	(58)	(82)	(148)
	EBT margin, %	0.00	0.00	0.00	—	(3,729.31)	0.00	0.00	0.00	0.00	0.00
	Net income	0	0	0	—	(24)	(54)	(36)	(58)	(82)	(148)
	Depreciation	—	—	—	—	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	—	0.25	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.01)	(0.02)	(0.01)	—	(9.51)	(12.17)	(7.22)	(7.22)	(4.02)	(4.25)
	Cash flow	0.00	(0.02)	0.00	—	(5.48)	(8.20)	(7.36)	(6.16)	(3.58)	(3.83)
	Capex	0.00	0.00	0.00	—	(0.07)	(0.09)	(0.51)	(0.06)	(0.07)	(0.04)
	Free cash flow	0.00	(0.02)	0.00	—	(5.55)	(8.29)	(7.87)	(6.22)	(3.65)	(3.87)
	Book value	0.02	0.03	0.02	—	24.81	13.81	7.48	26.10	8.16	6.66
	Shares, m	14	12	14	—	3	4	5	8	20	35
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	—	—	—	—	—
	P/S	—	—	—	—	0.00	—	—	—	—	—
	P/B	—	—	—	—	87.26	—	—	—	—	—
	EV/Sales	—	—	—	—	0.00	—	—	—	—	—
	EV/FCF	—	—	—	—	(399.06)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	0	0	0	—	(14)	(36)	(36)	(51)	(72)	(133)
	Capex	0	0	0	—	0	0	(3)	(1)	(1)	(1)
	Free cash flow	0	0	0	—	(15)	(36)	(38)	(52)	(74)	(135)
Balance, $m
Balance, $m	Working capital	0	0	0	—	47	40	13	155	101	165
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	0	0	0	—	(49)	(43)	(13)	(155)	(94)	(157)
	Shareholders’ equity	0	0	0	—	65	61	36	216	165	232
Returns, %
Returns, %	ROA	(27.85)	(49.89)	(22.78)	—	(69.65)	(78.84)	(66.63)	(43.74)	(40.42)	(68.67)
	ROIC	0.00	0.00	0.00	—	(86.35)	(177.22)	(101.89)	(59.41)	(90.68)	(119.57)
	ROE	(34.07)	(61.02)	(23.59)	—	(74.49)	(85.63)	(73.89)	(45.77)	(42.79)	(74.60)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
VSTM Verastem, Inc.	$835.9M	— (loss-making)	— (loss-making)	+1,775.43% (above 0%: growing)	n/m	−34.43% (below 0%: shrinking)	89.92%	(81.62%)	Compare
CRVS Corvus Pharmaceuticals, Inc.	$828.6M	— (loss-making)	—	—	n/m	−171.31% (below 0%: shrinking)	0.00%	0.00%	Compare
AVBP ArriVent BioPharma, Inc.	$827.9M	— (loss-making)	—	—	n/m	−51.51% (below 0%: shrinking)	—	0.00%	Compare
ARDX Ardelyx, Inc.	$814.9M	— (loss-making)	— (loss-making)	+23.77% (above 0%: growing)	n/m	+75.33% (above 0%: growing)	95.24%	(10.28%)	Compare
HELP Cybin Inc.	$807.3M	— (loss-making)	— (loss-making)	—	n/m	−25.60% (below 0%: shrinking)	0.00%	0.00%
DNA Ginkgo Bioworks Holdings, Inc.	$791.9M	— (loss-making)	— (loss-making)	−48.49% (below 0%: shrinking)	n/m	−16.38% (below 0%: shrinking)	91.47%	(290.47%)	Compare
GERN Geron Corporation	$790.2M	— (loss-making)	— (loss-making)	+17.22% (above 0%: growing)	n/m	+41.82% (above 0%: growing)	83.92%	(21.74%)	Compare
Median of peers	$828.2M	—	—	+20.50%	—	−25.40%	91.47%	(51.68%)

All 614 Biotechnology stocks →

Cybin Inc. (HELP) key facts

Cybin Inc. (HELP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HELP traded at $10.55, a market capitalization of $807.3 million.
Return on equity was −74.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.